ReviewClinical and experimental immunology2019
Novel multi-component vaccine approaches for Burkholderia pseudomallei.
Review in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- An outer membrane vesicle vaccine prevents lung pathology in a macaque model of pneumonic melioidosis.Nature communications · 2025Article
- Metabolomic profiling ofmSystems · 2025Article
- Multi-scale computational modeling to identify novel chemical scaffolds as trehalose-6-phosphate phosphatase inhibitors to combatIn silico pharmacology · 2025Article
- Melioidosis vaccines: recent advances and future directions.Frontiers in immunology · 2025Review
- Comparison of homologous and heterologous vaccination strategies for combating disease caused byFrontiers in immunology · 2025Article
- Burkholderia pseudomallei and melioidosis.Nature reviews. Microbiology · 2024Review
- Shared challenges to the control of complex intracellular neglected pathogens.Frontiers in public health · 2024Review
- NHP BurkPx: A multiplex serodiagnostic bead assay to monitor Burkholderia pseudomallei exposures in non-human primates.PLoS neglected tropical diseases · 2023Article
- Development of Melioidosis Subunit Vaccines Using an Enzymatically Inactive Burkholderia pseudomallei AhpC.Infection and immunity · 2022Article
- Burkholderia pseudomallei JW270 Is Lethal in the Madagascar Hissing Cockroach Infection Model and Can Be Utilized at Biosafety Level 2 to Identify Putative Virulence Factors.Infection and immunity · 2022Article
- Monitoring Laboratory Occupational Exposures toApplied biosafety : journal of the American Biological Safety Association · 2022Article
- Designing a novel chimeric multi-epitope vaccine againstFrontiers in medicine · 2022Article
- Hcp1-loaded staphylococcal membrane vesicle vaccine protects against acute melioidosis.Frontiers in immunology · 2022Article
- Predictive and Experimental Immunogenicity ofVaccines · 2021Article
- Recent Progress inPathogens (Basel, Switzerland) · 2021Review
- Antigen-specific antibody and polyfunctional T cells generated by respiratory immunization with protective Burkholderia ΔtonB Δhcp1 live attenuated vaccines.NPJ vaccines · 2021Article
- Review
- Melioidosis Patient Survival Correlates With Strong IFN-γ Secreting T Cell Responses Against Hcp1 and TssM.Frontiers in immunology · 2021Article
- Spatiotemporal Distribution of the Environmental Microbiota in Food Processing Plants as Impacted by Cleaning and Sanitizing Procedures: the Case of Slaughterhouses and Gaseous Ozone.Applied and environmental microbiology · 2020Article
- Combating the great mimicker: latest progress in the development ofExpert review of vaccines · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkholderia pseudomallei is the causative agent of melioidosis. Historically believed to be a relatively rare human disease in tropical countries, a recent study estimated that, worldwide, there are approximately 165 000 human melioidosis cases per year, more than half of whom die. The bacterium is inherently resistant to many antibiotics and treatment of the disease is often protracted and ineffective. There is no licensed vaccine against melioidosis, but a vaccine is predicted to be of value if used in high-risk populations. There has been progress over the last decade in the pursuit of an effective vaccine against melioidosis. Animal models of disease including mouse and non-human primates have been developed, and these models show that antibody responses play a key role in protection against melioidosis. Surprisingly, although B. pseudomallei is an intracellular pathogen there is limited evidence that CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.